MAP2K7 and melanoma: A 2023 systematic review demonstrated that BRAF and MEK inhibitor combination therapy decreased the risk of progression or death compared to monotherapy in women with BRAF-mutant melanoma with a pooled progression-free survival and overall survival hazard ratio of 0.50 (95% CI 0.41–0.61).